Jim Rae has more than 30 years of experience in the manufacturing, marketing, financial, human resource and R & D operations of pharmaceutical and biotechnology firms. He is experienced in raising funds and financing from public, private and government sectors.

Mr. Rae is President and founder of Remedis, a consultancy specializing in the restructuring and financing of health care businesses. Career highlights also include: Chairman of the Board of Directors of Bioniche Life Sciences Inc., President and CEO of Viron Therapeutics Inc., and President and CEO of Cangene; Chairman and CEO of Vaxis Therapeutics Inc.; Chairman and CEO of Resolution Pharmaceuticals; and CEO of Cytochroma Inc.

Mr. Rae is the Chairman of Queen’s Scientific Breakthrough Fund and holds directorships in a number of Canadian biotech companies.

Don Stewart is an entrepreneur and scientist with more than 20 years of management experience in the biotechnology industry. He is also the founder and President of Alba Biologics Group.

Dr. Stewart served as Director Research of Cangene Corporation from 1997 to 2007. At Cangene, he led programs to develop monoclonal antibodies and recombinant protein drugs; supervised animal efficacy and toxicology studies as well as clinical trial programs; and obtained more than $15 million in external grant and contract funding over a five-year period.

Dr. Stewart has a PhD in biochemistry from the University of London in the U.K. He has given numerous lectures at international symposia on research management, manufacturing strategies and biosimilar pharmaceuticals.

Dr. Chris Hall is a world expert in the science of plant-based pharmaceutical production. He is a University Professor Emeritus in the School of Environmental Sciences at the University of Guelph and a former Tier 1 Canada Research Chair in Recombinant Antibody Technology (2002-2014).

Dr. Hall leads a dynamic team of PlantForm researchers who, with every new discovery, take another step towards establishing the company’s plant-based manufacturing platform as a superior system for biopharmaceutical production.

Dr. Hall first recognized the manufacturing and regulatory advantages of using tobacco plants to produce antibody drugs in the early 1990s. His technology overcomes a number of issues associated with animal-derived antibody production: it allows for higher yields, lowers costs and eliminates animal welfare concerns.

Dr. Hall’s research group also studies the large-scale production of antibodies in plants against food- and water-borne pathogens, biological weapons and environmental contaminants. His laboratory has published more than 150 papers in refereed journals.

Ashley Meyers has over 10 years of experience in biopharmaceutical development that includes research and development of recombinant proteins and production of these products for pre-clinical studies. Ms. Meyers has been leading medical countermeasure research and development programs since 2012 and has collectively secured over $2.2 million towards advancing these programs. She has over five years of experience as a project manager for government-funded contracts for PlantForm Corporation.

Ms. Meyers completed a MSc degree in protein engineering in plants from the University of Guelph under the supervision of Dr. J. Christopher Hall, PlantForm’s co-founder and Chief Scientific Officer.

Warren Whitehead is a Certified Management Accountant who has held several senior financial management positions with pharmaceutical and biotechnology firms. He is the former CFO of Arius Research Inc., an anti-cancer antibody company (acquired by Roche in 2008), and former CFO of Labopharm Inc. (2000 to 2006) where he led several rounds of financing, including a cross-border NASDAQ offering. Prior positions include CFO of Resolution Pharmaceuticals Inc. and finance and business development at Glaxo Canada (now GlaxoSmithKline).

Mr. Whitehead holds an MBA from the University of Windsor.